Fabry disease presenting with renal disease as the main manifestation diagnosed by renal biopsy: a case report
Received date: 2021-05-11
Online published: 2022-11-07
法布里病（Fabry disease, FD）是一种X染色体连锁隐性遗传性疾病,主要由于半乳糖苷酶A（galactosidase A,GLA）基因突变,导致其编码的α-GLA活性下降或丧失,最终引起其代谢底物沉积于多个器官而致病,肾脏和心脏是两大最主要的受累器官。既往所报道的FD患者一般依据明确的家族史且合并致病基因突变而被明确作诊断。本文报道一例肾小球肾炎为主要表现的FD患者,外显子测序结果未见GLA相关基因突变,但肾脏病理活检发现肾小管上皮细胞细胞质内有典型的髓样小体,结合患者α-GLA活性下降,为26.2 nmol/（mL·h·m）[参考值>37 nmol/（mL·h·m）],故而确诊。本病例提示肾脏病理检查在该病诊断中的作用。
郝旭, 王伟铭 . 依靠肾活检确诊的以肾脏病变为主要表现的法布里病1例报告[J]. 诊断学理论与实践, 2022 , 21(04) : 527 -529 . DOI: 10.16150/j.1671-2870.2022.04.019
Fabry′s disease is an X-linked recessive genetic disease, which is mainly due to the mutation of (galactosidase A, GLA) gene. The decrease or loss of GLA activity eventually leads to the deposition of its metabolic substrate in multiple organs of the body, in which the kidney and heart are the two main affected organs. This paper reports a case of Fabry disease without gene mutation and diagnosed by renal biopsy and derease of GLA activity[26.2 nmol/(mL·h·m)][refer-ence value: >37 nmol/(mL·h·m)], clarifying the role of renal pathology in the diagnosis of the disease.
Key words： Fabry disease; Alpha-galactosidase A; Gene mutation; Proteinuria
| [1] | Rombach SM, Hollak CE, Linthorst GE, et al. Cost-effectiveness of enzyme replacement therapy for Fabry disease[J]. Orphanet J Rare Dis, 2013, 8:29. |
| [2] | 中国法布里病专家协作组. 中国法布里病(Fabry病)诊治专家共识[J]. 中华医学杂志, 2013, 93(4):243-247. |
| [2] | Chinese expert collaboration group on Fabry disease. Expert consensus on diagnosis and treatment of Fabry disease in China[J]. Natl Med J China, 2013, 93(4):243-247. |
| [3] | 潘晓霞, 欧阳彦, 王朝晖, 等. 法布里病83例临床病理特点分析[J]. 中国实用内科杂志, 2014, 34(3):262-266. |
| [3] | Pan XX, Ouyang Y, Wang CH, et al. Clinical and pathological characteristics of 83 cases of Fabry disease[J]. Chin J Pract Int Med, 2014, 34(3):262-266. |
| [4] | MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males[J]. J Med Genet, 2001, 38(11):750-760. |
| [5] | Tanaka M, Ohashi T, Kobayashi M, et al. Identification of Fabry′s disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients[J]. Clin Nephrol, 2005, 64(4):281-287. |
| [6] | Bekri S, Enica A, Ghafari T, et al. Fabry disease in patients with end-stage renal failure: the potential benefits of screening[J]. Nephron Clin Pract, 2005, 101(1):c33-c38. |
| [7] | Gal A, Hughes DA, Winchester B. Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group[J]. J Inherit Metab Dis, 2011, 34(2):509-514. |
| [8] | Patel V, O'Mahony C, Hughes D, et al. Clinical and genetic predictors of major mardiac events in patients with Anderson-Fabry disease[J]. Heart, 2015, 101(12):961-966. |
| [9] | Hagège A, Réant P, Habib G, et al. Fabry disease in cardiology practice: Literature review and expert point of view[J]. Arch Cardiovasc Dis, 2019, 112(4):278-287. |
| [10] | Yogasundaram H, Kim D, Oudit O, et al. Clinical features, diagnosis, and management of patients with anderson-Fabry cardiomyopathy[J]. Can J Cardiol, 2017, 33(7):883-897. |
| [11] | Schiffmann R, Swift C, McNeill N, et al. Low frequency of Fabry disease in patients with common heart disease[J]. Genet Med, 2018 Jul, 20(7):754-759. |
| [12] | Capelli I, Aiello V, Gasperoni L, et al. Kidney transplant in Fabry disease: a revision of the literature[J]. Medicina (Kaunas), 2020, 56(6):284. |
/
| 〈 |
|
〉 |
